Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic HLA-identical bone marrow-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Itziar Astigarraga Aguirre
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic HLA-identical bone marrow-derived mesenchymal stem cells (MSCs) is an investigational cell therapy being evaluated for the treatment of osteogenesis imperfecta (OI), specifically type III OI caused by mutations in the COL1A1 or COL1A2 genes. The therapy involves the repeated intravenous infusion of non-mutated, histocompatible (HLA-identical or sharing at least 5 out of 6 HLA antigens) MSCs obtained from healthy donor bone marrow. These cells are intended to home to the bone, engraft, and differentiate into functional osteoblasts that produce normal type I collagen, thereby improving bone strength and reducing fracture frequency in pediatric patients. A key feature of this protocol is the absence of immunosuppressive therapy, leveraging the low immunogenicity and immunomodulatory properties of MSCs. The therapy is currently being investigated in a Phase 1 clinical trial in Spain led by Itziar Astigarraga Aguirre.
- Other names
- HLA-identical mesenchymal stem cellsallogeneic bone marrow-derived mesenchymal stem cellsHLA-identical mesenchymal stem cell therapy
Beyond the preview
Go deeper on allogeneic HLA-identical bone marrow-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic HLA-identical bone marrow-derived mesenchymal stem cells.